Yes the crystalisation problem remained to be solved even if Lederle had chosen to abandon bisantrene because their CEO hated the colour orange.
This crystalisation problem is now solved, the IP is vastly stronger and broader, and we now know and can advance the massive CPACS and m6A RNA opportunities.
- Forums
- ASX - By Stock
- Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
Yes the crystalisation problem remained to be solved even if...
-
- There are more pages in this discussion • 356 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.63 |
Change
-0.035(2.11%) |
Mkt cap ! $278.6M |
Open | High | Low | Value | Volume |
$1.68 | $1.68 | $1.61 | $91.17K | 56.05K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4572 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.64 | 804 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4572 | 1.625 |
2 | 7543 | 1.620 |
2 | 30930 | 1.615 |
2 | 16249 | 1.610 |
3 | 24875 | 1.600 |
Price($) | Vol. | No. |
---|---|---|
1.635 | 804 | 2 |
1.640 | 2577 | 1 |
1.645 | 5264 | 1 |
1.650 | 1975 | 1 |
1.665 | 845 | 1 |
Last trade - 12.21pm 06/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |